Archived Events and Presentations
| Date | Event Details |
|---|---|
| Nov 12, 2021 | American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2021 |
| Nov 04, 2021 | American Society of Nephrology (ASN) Kidney Week 2021 |
| Oct 18, 2021 | The Science of HBV Cure Conference |
| Aug 05, 2021 | PHYOX™2 Top-Line Results |
| Jun 11, 2021 | 2021 Alpha-1 National Conference |
| Apr 28, 2021 | Oligonucleotides: Chemistry & Therapeutics Symposium |
| Apr 12-16, 2021 | AMCP 2021 |
| Mar 30, 2021 | Oligonucleotide and Precision Therapeutics (OPT) Virtual Congress |
| Mar 18, 2021 | DCR-AUD Webinar |
| Nov 16, 2020 | AASLD The Liver Meeting® Digital Experience™ 2020 : HBV RNAi inhibitor RG6346 in Phase 1b-2a trial was safe, well-tolerated, and resulted in substantial and durable reductions in serum HBsAg levels |
| Nov 10, 2020 | TIDES Europe 2020 Presentation |
| Oct 22, 2020 | American Society of Nephrology (ASN) Kidney Week 2020 Posters |
| Aug 06, 2020 | 2020 Virtual R&D Event |
| Jun 26, 2020 | Virtual Alpha-1 National Conference, Emerging Therapies in Alpha-1 DCR-A1AT as a Potential Therapeutic for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease |
| Jun 21, 2019 | OHF International Workshop Data Poster – June 2019 |
| Mar 29, 2019 | PHYOX ™: A Safety and Tolerability Study of DCR-PHXC in Primary Hyperoxaluria Types 1 and 2 |
| Nov 09, 2018 | Dicerna HBV AASLD Poster 2018 |
| Oct 25, 2018 | Dicerna PHYOX ASN Poster 2018 |
